Novel cell-free and concentrated ascites reinfusion therapy (KM-CART) for refractory ascites associated with cancerous peritonitis: Its effect and future perspectives

Department of Surgery, Hofu Institute of Gastroenterology,14-33 Eki-minami, Hofu 747-0801, Japan.
International Journal of Clinical Oncology (Impact Factor: 2.13). 02/2011; 16(4):395-400. DOI: 10.1007/s10147-011-0199-1
Source: PubMed


We have actively carried out cell-free and concentrated ascites reinfusion therapy (CART) for refractory ascites. However, with conventional CART, the membrane becomes clogged after processing about 2 L of cancerous ascites fluid due to the fact that it is rich in cellular and mucous components; it is therefore difficult to process the entire volume of collected ascites.
We developed KM-CART which includes a membrane cleaning function, and applied it in 73 cases of cancerous ascites, after its basic functions had been evaluated in 11 cases of refractory cancerous ascites.
On average, using KM-CART, 6.4 L (range 1.7-14.9 L) of ascites were filtrated and concentrated to 0.8 L (0.2-2.0 L) in 57 min (5-129 min); the membrane was cleaned an average of three times (range 0-10 times) and this enabled the processing of more ascites in a shorter period. In addition, the circuit and the handling were both markedly simple, and fever, which has been the most notable adverse effect with the conventional system, was not an issue.
Since KM-CART was safe and is expected to improve the subjective symptoms and general condition of the patient, it is proposed that this novel system should actively be used not only for palliation but also as supplementary treatment for cancerous peritonitis.

1 Follower
45 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The management of malignant ascites is critical for the treatment of patients with advanced gynecological cancer. The purpose of this study was to assess the clinical significance of cell-free and concentrated ascites re-infusion therapy (CART). Adverse events, alterations in Eastern Cooperative Oncology Group performance status, serum albumin, body weight and abdominal circumference, and overall survival were examined in 22 patients with advanced gynecological cancer which were treated with CART. Most of the adverse events were grade 1 or 2 fever. CART treatment had little effect on ECOG performance status and on levels of serum albumin. There was a significant decrease in body weight and in abdominal circumference post-treatment with CART, relative to pre-treatment (p<0.01). The overall survival rate was significantly prolonged in 14 patients after CART plus chemotherapy, as compared with eight patients after CART alone (p<0.01). CART may contribute to the improvement of quality of life and of survival in patients with advanced gynecological cancer.
    Anticancer research 06/2012; 32(6):2353-7. · 1.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A 58-year-old man was admitted to the hospital because of ascites due to alcohol-related cirrhosis, which was refractory to salt-restricted diet and diuretics. He showed no improvement even after the administration of albumin preparation and developed hepatic encephalopathy due to intravascular volume depletion. Ascites decreased when cell-free concentrated ascites reinfusion therapy (CART) was introduced, without developing hepatic encephalopathy. After introducing temperance guidance, the serum albumin level increased from 2.4 g/d/to 3.6 g/d/ and the Child-Pugh score improved from 12 points to 6 points. CART is defined in the clinical practice guideline for liver cirrhosis in Japan that it is as effective as total paracentesis but would not improve the prognosis. However, it was considered from this case that CART is useful for refractory ascites with decompensated cirrhosis because CART do not occur hepatic encephalopathy.
    Kanzo 01/2013; 54(9):614-619. DOI:10.2957/kanzo.54.614
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sinusoidal obstruction syndrome (SOS) is one of the severe complications of hematopoietic stem cell transplantation (HSCT). Systemic management including respiratory and circulatory support is necessary. In addition, abdominal paracentesis is often needed for pain relief and to reduce the pressure of tense ascites. Concentrated ascites reinfusion therapy (CART) involves the filtration, concentration, and reinfusion of drained ascites, which contributes to reuse of autologous proteins. CART has been reported as supportive therapy for patients with liver cirrhosis and cancer. We retrospectively reviewed the efficacy and safety of CART in three patients (two with acute myelogenous leukemia and one with chronic myeloid leukemia) who developed SOS after allo-HSCT. They all had symptomatic, tense, and diuretic-refractory ascites with right costal pain and marked weight gain. Two patients showed immediate improvement after CART. However, one patient experienced four CARTs with slow recovery. All patients are now alive and are being monitored as outpatients over 2 years with remission. No severe adverse event was observed related to CART, and 25.2-98.0 (median 30.2) grams of albumin was collected and reinfused. CART after paracentesis reduces protein loss in ascites by reinfusion of autologous protein instead of exogenous albumin preparations. Although transient fever is reported as a frequent adverse event, no events like severe bleeding or infection were observed. While its safety has not been fully established in patients with hematological disease after HSCT, CART may be a considerable supportive therapy for SOS with tense ascites.
    Artificial Organs 05/2013; 37(10). DOI:10.1111/aor.12080 · 2.05 Impact Factor
Show more

Similar Publications